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Abstract
Bcl-XL, an antiapoptotic Bcl-2 family protein, plays a central role in the regulation of the apoptotic pathway.
Heterodimerization of the antiapoptotic Bcl-2 family proteins with the proapoptotic family members such as Bad, Bak,
Bim and Bid is a crucial step in the apoptotic regulation. In addition to these conventional binding partners, recent
evidences reveal that the Bcl-2 family proteins also interact with noncanonical binding partners such as p53. Our previous
NMR studies showed that Bcl-XL: BH3 peptide and Bcl-XL: SN15 peptide (a peptide derived from residues S15-N29 of p53)
complex structures share similar modes of bindings. To further elucidate the molecular basis of the interactions, here we
have employed molecular dynamics simulations coupled with MM/PBSA approach. Bcl-XL and other Bcl-2 family proteins
have 4 hydrophobic pockets (p1–p4), which are occupied by four systematically spaced hydrophobic residues (h1–h4) of
the proapoptotic Bad and Bak BH3 peptides. We observed that three conserved hydrophobic residues (F19, W23 and L26) of
p53 (SN15) peptide anchor into three hydrophobic pockets (p2–p4) of Bcl-XL in a similar manner as BH3 peptide. Our results
provide insights into the novel molecular recognition by Bcl-XL with p53.
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Introduction
Apoptosis or programmed cell death is a key regulatory process
involved in major biological pathways in which its dysregulation is
linked to cancer, autoimmunity, and neurodegenerative disorders
[1]. The Bcl-2 family proteins regulate and mediate the
mitochondrial outer membrane permeabilization, a crucial event
in the mitochondrial pathway of apoptosis in vertebrates [2–5].
The regulation of apoptosis is governed largely by interactions
between the pro-survival and pro-death members of the Bcl-2
protein family [6]. Some members of this family (e.g., Bax, Bak,
and Bid) promote apoptosis, while others such as Bcl-XL, Bcl-2
and Bcl-w work against programmed cell death [7,8]. The Bcl-2
family proteins are characterized by regions of specific sequence
homology named as Bcl-2 homology (BH) motifs that number
from 1 to 4 and are critical for function [9]. Especially a-helical
BH3 motif of proapoptotic proteins occupy and form strong
interactions with hydrophobic groove of antiapoptotic Bcl-2 family
proteins which leads to the activation of the essential death
mediators Bax and Bak, thereby committing cells to apoptosis
[10–15].
p53, a key tumor suppressor protein also termed as ‘‘the
guardian of the genome’’, plays a key role in cellular stress
response pathway [16,17]. It is found to be mutated or lost in more
than 50% of all human cancers indicating its crucial functions in
controlling tumor formation [18]. Under normal conditions, p53 is
quiescent and present at basal levels. Upon cellular stress, DNA
damage and hypoxia, it is upregulated and induces pathways that
cause cell cycle arrest, DNA repair, cellular senescence, differen-
tiation and apoptosis [19,20]. The proapoptotic activity of the
tumor suppressor protein p53 is controlled by a number of
protein–protein interactions that constitute a network of negative
and positive regulators [21]. The central part of this network is the
interaction with the oncogenic protein MDM2 via the N-terminal
transactivation domain (TAD) and the central DNA-binding
domain (DBD) [22,23]. Binding of the E3 ubiquitin ligase, MDM2
to the tumor suppressor protein, targets p53 for proteosomal
degradation [24].
While the transcription-dependent mechanism of p53 has been
extensively studied [25], evidence supporting the transcription-
independent apoptotic activity of p53 has emerged in recent years
[26,27]. This suggests that p53 could be localized in the outer
membrane of mitochondria and execute the transcription-
independent apoptotic cell death in response to death signals
[28,29]. Recent studies on the transcription-independent mito-
chondrial p53 apoptotic pathway provided valuable information
[30–34]. It was demonstrated that PUMA, a proapoptotic BH3
only protein releases p53 from Bcl-XL/p53 complex and allows
Bax or Bak to induce mitochondrial permeability [33] while p53
upregulated Bad, another proapoptotic protein by forming a
complex in the mitochondria thereby inducing apoptosis [34].
These studies revealed that Bcl-2 family proteins are the binding
targets for p53 and results in a transcription-independent
apoptotic activity.
The structures of Bcl-XL in complex with Bad or Bak
proapoptotic BH3 peptides offer detailed structural information
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peptide residues [35,36], revealing possible hydrophobic pockets
and important interactions which provide a molecular basis to
develop sub-nanomolar range inhibitors [37]. Similarly, studies on
MDM2/p53 complex studies also contributed to the designing of
antagonists to disturb p53-MDM2 interactions [38–40]. Based on
this structural information, several p53 peptidomimetics were
developed [41–43]. Computational studies provided insightful
information into the molecular recognition between p53 and
MDM2 [44–48]. In previous NMR studies we have attempted to
understand the binding properties of p53 with its non-conven-
tional partner Bcl-XL, and based on those observations we
developed a complex model [49,50]. In the present study we have
performed several molecular dynamics simulations on Bcl-XL/
BH3 peptides (Bad, Bak), MDM2/p53 and Bcl-XL/p53 (SN15)
peptide complexes and examined the common interaction pattern
of these peptides with their binding partners using multiple
conformations. Binding free energy calculations and residual
decomposition analyses were opted to understand recognition
process of these peptides by Bcl-XL.
Methods
Starting structures
The initial coordinates of MDM2/p53 and Bcl-XL/BH3
peptide complexes were obtained from the Protein Data Bank.
The wild type human p53 (residues 17–29) and MDM2 (residues
25–109) complex crystal structure with PDB ID: 1YCR was
utilized [38]. Two proapoptotic proteins Bad and Bak BH3
peptides in complex with human Bcl-XL (PDB ID 1G5J and
1BXL respectively) were considered as starting structures for Bcl-
XL/BH3 peptide complex simulations [35,36]. The Bcl-XL/SN15
peptide complex coordinates were taken from our previous model
developed by using HADDOCK based on chemical shift
perturbations observed for Bcl-XL upon complex formation with
SN15 peptide [50].The Bcl-XL/Bak BH3 peptide complex
structure (PDB ID: 1BXL) was utilized to develop the Bcl-XL/
SN15 peptide complex model. The N- and C-terminus residues of
the proteins were capped with ACE and NME, accordingly to
keep them neutral at the time of simulation. The N-terminal end
alone was capped for peptide in the MDM2/p53 complex, based
on previous computational studies [45–48].
Molecular dynamics simulations
All the MD simulations were performed using GROMACS
software (version 4.0.5) [51,52] with the Amber99 force field. The
MD simulation protocol that we used is as follows. Hydrogens were
added and the protonation state of ionizable groups was chosen
appropriate to pH 7.0. Each system was inserted in a water box of
TIP3P water, which extended at least 12 A ˚ away from any given
protein atom. All systems were neutralized by adding counter ions
and replacing the overlapping solvent molecules. The size of each
system utilized for the simulations are represented in Table 1. All
simulationswererununderperiodic boundaryconditions with NPT
ensemble by using Berendsen’s coupling algorithm for maintaining
the temperature (300 K) and the pressure constant (1 bar). The
SHAKE algorithm with a tolerance of 10
25 A ˚ was applied to fix all
bonds containing hydrogen atoms. The electrostatic interactions
were calculated by using the Particle-mesh Ewald (PME) algorithm,
with interpolation order of 4 and a grid spacing of 0.1 nm and the
van der Waals forces were treated by using a cutoff of 10 A ˚. A 2-fs
time step wasused to integrate the equations ofmotion. The systems
were subjected to steepest descent energy minimization for 2,000
steps. Then the protein backbone was frozen and the solvent
molecules with counter ions were allowed to move during a 200 ps
position restrained MD run. The final production run continued for
10 or 15 ns (Table 1) and the coordinates were stored every 1 ps.
The purpose of the simulations was to generate multiple structures
around the initial experimental/model structure to improve the
statistical sampling for binding free energy (DGbind) calculations
using MM/PBSA method.
Binding free Calculations
The binding energy of protein-peptide complexes was calculated
by using MM/GBSA (for MDM2/p53) and MM/PBSA (for
remaining simulations) incorporated in Amber9 package [53–55].
MDM2/p53 simulation was utilized to benchmark our MD
simulation protocol as this system is well studied by computational
simulations. The trajectory files generated by production run of
different systems are converted into individual PDB files by trajconv
methodincorporatedinGROMACSanalysissuite.ForMDM2/p53
and Bcl-XL/SN15W23A mutant simulation (10 ns each) 2500
snapshots were considered at the time intervals of 2 ps from the
last5 nsproduction runs.For remaining three 15 nssimulations(Bcl-
XL with Bad, Bak and SN15 peptides) 5000 snapshots were chosen
fromthe last10 ns. These selected snapshots were utilized to calculate
the enthalpy contributions of protein-peptide complexes and every
100
th snapshot of selected frames (25 or 50 frames for 2500 or 5000
snapshots, respectively) was used to calculate entropy terms using
normal mode analysis (Nmode module of Amber) and averaged [56].
The dielectric constants for solute and solvent set as 1.0 and 80.0,
respectively. The solvent accessible surface area (SASA) was
computed with molsurf module in Amber9, using a probe radius of
1.4 A ˚ [57]. The surface tension proportionality constant and the free
energy of nonpolar solvation of a point solute were set to
0.00542 kcal/A ˚ 2 and 0.92 kcal/mol, respectively. A single trajectory
method was used in MM-GBSA/PBSA binding free energy
calculations. Residual decomposition analysis which is incorporated
in the Amber9 software package was utilized to understand the
important interactions between protein-peptide complexes and also
to select the crucial hot spot interactions which are essential for the
complex formation and stability. Every 50
th snapshot of selected
frames (50 or 100 frames for 2500 or 5000 snapshots, respectively)
was used to calculate the energy decomposition for all the protein and
peptide residues. All the preliminary analyses to ensure the quality of
the simulations such as root mean square deviation (RMSD), root
means square fluctuation (RMSF), secondary structural analyses by
DSSP are carried out by GROMACS analysis programs.
Results
Sequence comparison of BH3 and SN15 peptides
Antiapoptotic proteins such as Bcl-XL, Bcl-2, Bcl-w and Mcl-1
possess four conserved hydrophobic pockets (p1–p4) which
Table 1. Summary of MD simulations performed in present
study.
System Initial coordinates No. of atoms Simulation length
MDM2/p53 1YCR 18,671 10 ns
Bcl-XL/Bad 1G5J 35,627 15 ns
Bcl-XL/Bak 1BXL 35,520 15 ns
Bcl-XL/SN15 Model 34,103 15 ns
Bcl-XL/SN15W23A Model 34,100 10 ns
doi:10.1371/journal.pone.0026014.t001
MD Simulations of Bcl-XL/p53 Complex
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the BH3 peptides of Bad and Bak. Sequence alignment was
carried out by clustalW method [58] to obtain initial insights of
similarities between the BH3 (Bad25 and Bak16) and SN15
peptides. We have failed to achieve a meaningful sequence
alignment by normal procedure of taking SN15 sequence in
conventional way (15SQETFSDLWKLLPEN29). Our previous
NMR chemical shift perturbation experiments and HADDOCK
model revealed that the binding orientation of SN15 peptide to
Bcl-XL is in opposite direction (29NEPLLKWLDSFTEQS15)
when compared to BH3 peptides such as Bad and Bak binding
orientations (Figure 1A–1D) [49,50]. Based on these previous
observations, the binding orientations of the peptides with Bcl-XL
were considered for sequence alignment i.e. Bad (N1RK25), Bak
(G1RR16) and SN15 (N29RS15). By this attempt, the sequences
aligned well and all the important hydrophobic residues that are
crucial for Bcl-XL binding are aligned properly (Figure 1E). These
results also revealed that SN15 has three hydrophobic residues
(L26, W23 and F19) which occupy three hydrophobic pockets (p2,
p3 and p4).
Preliminary analysis of MD simulations
Total five simulations were carried out for MDM2/p53
complex, Bcl-XL/Bad, Bcl-XL/Bak, Bcl-XL/SN15 and Bcl-
XL/SN15W23A, a SN15 point mutant peptide. The MD
simulations were judged to be stable as evidenced by the time
dependent evaluation of backbone root mean square deviation
(RMSD). The RMSD was calculated during production phase
using the respective initial minimized structure as the reference
structure. The average RMSD value for MDM2/P53 complex
simulation was 0.12 nm which is consistent with previous
computational simulation studies [45]. For the Bcl-XL/peptide
(SN15, Bad and Bak) simulations the average RMSD values was
between 0.28 nm to 0.32 nm. The Bcl-XL/SN15 mutant (W23A)
peptide simulation showed bit higher RMSD average values
(0.4 nm), which can be expected due to changes in the peptide
secondary structure and overall fluctuations of protein structure.
Comparatively high fluctuations were observed at the long flexible
loop of Bcl-XL located between a1 and a2 and also other loops
which connect the a-helices. These observations suggest that there
is no significant structural drift in each system during the MD
simulations (Figure 2). Secondary structural analysis was carried
out to measure the stability of the simulations. These analysis
shows that the a-helices present in the MDM2 as well as Bcl-XL
persist throughout the simulation time (Figure 3 and Figure S1A–
S1D). The short b-strands present in the MDM2 structures also
maintained their size (Figure S1A). The structural differences were
observed at the loop positions that connect the a-helices due to
high flexible nature. Previous experimental and computational
studies demonstrated that helical content of the peptides (p53 or
BH3 peptides) is directly proportional to its binding ability with
partners [47,59]. DSSP analysis revealed that all the peptides
indeed preserve their helical content and in several simulations
there is an increase by 2–3 residues (Figure 3 and Figure S1A–
S1D). The stability and increment in the helical content is also
evident from the intra-molecular hydrogen bonds between main
chain atoms of the peptides (Figure S2A–S2D).
Free energy decomposition of protein-peptide
complexes and comparison
We have adopted binding free energy calculations and
decomposition of residue wise contribution to understand the
similarities between BH3 domains of proapoptotic proteins (Bad
and Bak) and N-terminal transactivation domain of p53 (SN15).
These results also facilitate us to identify the key residues of p53
which are crucial for binding with MDM2 and novel binding
partner Bcl-XL. For the purpose of this work and to identify hot
spot amino acids in protein and peptide complexes, we defined key
residue as the one that makes a 21 kcal/mol contribution to the
binding free energy.
Energy calculations for MDM2 with p53 peptide
Binding free energy calculations were carried out for MDM2/
p53 complex to better understand the interaction pattern of p53
with MDM2 as well as to unveil the hot spot residues of p53 which
are common in complex formation with MDM2 and Bcl-XL. This
simulation results also allowed us to compare with previous
computational studies and benchmark our MD simulation
protocol. For this purpose we have opted MM/GBSA method
to calculate the binding free energy of MDM2/p53 complex. The
DGbind of this complex was computed as 211.3 kcal/mol (Table 2
and Table 3) which is close to experimental binding free energy
(26.4 to 29.0 kcal/mol) [60,61] and other computational studies
estimates 26.9 to 216 kcal/mol [44–48]. The residue level
contribution was carried out to extract the key residues
information from both protein (MDM2) and peptide. The results
suggest that the residues, F19, W23 and L26 of p53 contribute
Figure 1. Binding orientation and sequence comparison of
SN15 with BH3 peptides. The interaction pattern of Bcl-XL and Bad
(A), Bak (B), SN15 (C) was shown. All the three peptides represented as
cartoon and Bcl-XL as surface. Hydrophobic residues of the peptides
which occupy the four hydrophobic pockets (p1–p4) are highlighted by
sticks and labeled accordingly. All the three peptides (Bad, Bak and
SN15) superimposed and the important interacting regions of Bcl-XL
such as BH1, BH2 and BH3 are highlighted with magenta, red and gray,
respectively (D). Shown is sequence comparison between SN15 and Bad
and Bak. Four important binding points (h1–h4) are highlighted by
green boxes, identical residues and conserved residues are highlighted
by red and yellow colors, respectively (E).
doi:10.1371/journal.pone.0026014.g001
MD Simulations of Bcl-XL/p53 Complex
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binding than W23 (Table 4), which is consistent with previous
computational observations [48]. Several hydrophobic and one or
two hydrophilic MDM2 residues which are important in complex
formation were also identified (Figure 4A).
Binding free energy calculations and their decomposition
for Bcl-XL/peptide complexes
The Bcl-XL/BH3 peptide complexes were well studied as the
three dimensional structures were solved by either NMR or X-ray
crystallographic methods and also by computational studies
[35,36]. But the interaction pattern between Bcl-XL and p53
(SN15) and the key residues which are involved in the complex
formation is not fully known. The calculated DGbind was 217.7
and 212.3 kcal/mol for Bcl-XL/Bad and Bcl-XL/Bak complexes
respectively (Table 2, Table S1 and S2). The experimental
methods estimated 212.7 and 28.94 to 29.32 kcal/mol for Bcl-
XL/Bad and Bcl-XL/Bak complexes respectively [35,36]. Our
previous experimental binding studies between Bcl-XL/SN15
peptide estimated DGbind as 24.95 kcal/mol [50] and present
computational binding free energy method estimated 27.3 kcal/
mol (Table 5). These results demonstrate that computational free
energies are estimated close to the experimental binding values
with acceptable differences. The residual decomposition results
identified that several residues of Bcl-XL which are important for
heterodimer formation with BH3 peptides like Bad/Bak are
indeed important for complex formation with SN15 with fewer
differences. The three hydrophobic residues (F19, W23 and L26)
of p53 which are important in complex formation with MDM2 are
also crucial for complex formation with Bcl-XL(Table 6).
Discussion
Key anchoring residues of p53 for MDM2 binding
The three hydrophobic residues (F19, W23 and L26) that
occupy the hydrophobic surface of the MDM2 are crucial for the
binding [62]. Previous experimental studies revealed that these
residues are susceptible for mutations which show severe decrease
in binding or even inactive in some cases [43]. Residue F19 of p53
which is predicted as major contributor (26.58 kcal/mol) for
MDM2 binding forms strong van der Waals contacts with I61 as
well as with G58, Y67 and V93. The tryptophan residue of p53
protrudes into hydrophobic pocket formed by several conserved
aliphatic hydrophobic residues like L54 and L57. The residual
level energetics revealed that L54 contributes strongly from
MDM2 part, this is due to both van der Waals contact with
tryptophan and also stable hydrogen bond. This hydrogen bond is
observed between NEe of tryptophan and main chain carbonyl of
L54. Another conserved hydrophobic residue L26 of p53 interacts
with I99 side chain. Our results are also consistent with previous
experimental and computational findings and corroborate that
these three hydrophobic residues of p53 are determinants for
MDM2 binding. Apart from these three crucial interactions
several other residues also helps for the firm binding such as L22,
P27 and T18. The residue L22 of p53 interacts with V93 and H73
of binding partner. Proline residue (P27) present on the p53
peptide forms van der Waals interactions with Y100 of MDM2.
Major contributors of BH3 peptides for hetero-
dimerization with Bcl-XL
Four conserved hydrophobic pockets (p1–p4) are available in all
the Bcl-2 family members like Bcl-XL, Bcl-2, Mcl-1 and Bcl-w
proteins. Most of the residues which form these hydrophobic
pockets are also conserved across the family members. All four
pockets are formed by residues present on BH1 (a4 and a5 helices)
majorly, BH2 (a7) and BH3 (a2) helices of Bcl-XL. These
hydrophobic pockets provide space for the well-spaced (i, i+4, i+7
and i+11) hydrophobic residues (h1–h4) on BH3 peptides such as
Bad/Bak (Figure 1A and 1B). The hydrophobic residues of BH3
peptides lock with binding partner by forming strong van der
Waals interactions. Several experimental and computational
studies demonstrated that these four hydrophobic residues are
crucial for heterodimer formation [35,36,44,63]. Residual decom-
position results illustrate that these four hydrophobic residues of
the Bad/Bak peptide contribute sufficiently well for binding with
the Bcl-XL (Table 6).
Residue Y8 of Bad peptide and V3 of Bak peptide occupies p1
hydrophobic pocket of Bcl-XL. This pocket is formed by F105,
L112, V126 and F146 which constitutes BH1 and BH3 helices and
a short a3 helix. A stable hydrogen bond interaction observed
between side chain hydroxyl of Bad Y8 and main chain carbonyl
Figure 2. RMSD plots for five MD simulations. The Root mean
square deviation (RMSD) of backbone atoms were shown with respect
to initial minimized structure for all the five simulations such as MDM2/
p53 (A), Bcl-XL/SN15 (B), Bcl-XL/Bad (C), Bcl-XL/Bak (D), and Bcl-XL/
SN15W23A (E).
doi:10.1371/journal.pone.0026014.g002
MD Simulations of Bcl-XL/p53 Complex
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V126, L130 as well as F146 and locks with conserved leucine
residue of BH3 peptides (L12, L7 of Bad and Bak, respectively).
The residue M15 of Bad peptide and I10 of Bak form van der
Waals interactions with p3 hydrophobic pocket formed by F97
and A142 residues. Finally the p4 pocket formed by F97 and V141
residues is occupied by F19 (Bad) and I14 (Bak). Besides these
crucial hydrophobic interactions, several other hydrophobic
interactions are observed to be important for binding. A5 residue
of Bad peptide contributed ,22.8 kcal/mol for complex
formation. This residue forms close contacts with L112, S122,
Q125 and V126 and make favorable contribution for binding
energy. Another hydrophobic residue F23 of Bad peptide forms
firm van der Waals contacts with L194 and Y195 of its binding
partner Bcl-XL. Previous point mutation studies of these two Bad
peptide residues (A5G and F23A) demonstrated ,4 fold less
binding affinity compared with wild type peptide also suggests the
important role of these residues for binding [36]. Previous
computational study also recognized these two residues as
probable hot spots of BH3 peptides for Bcl-2 family proteins
binding [44]. These strong interactions of A5 and F23 could be the
possible reasons for the extended alpha helical nature of the Bad
peptide appeared in the Bcl-XL/Bad peptide simulation (Figure
S1B).
Unlike MDM2 binding pocket which is mostly constructed by
hydrophobic residues, Bcl-XL surface is composed of both
hydrophobic and charged residues. The interior pocket is
hydrophobic and the wall of the binding pocket is composed of
charged residues. The Bad and less extent Bak peptides are having
several charged residues to complement the charge environment of
its binding partner. R10 of Bad peptide and R5 of Bak peptide
forms stable hydrogen bonds with E129 residue of Bcl-XL. Salt
bridge analysis incorporated in vmd program suite [64] was utilized to
determine salt bridge forming pairs between protein and peptide
complexes. This analysis revealed that salt bridges can be formed
between R10 (Bad)/R5 (Bak) and E129 of Bcl-XL. Another
arginine residue (R13) of Bad peptide form hydrophilic interac-
tions with D133 and also forms salt bridge. The equivalent residue
in Bak peptide is an alanine (A8) also contributes favorably
(22 kcal/mol) by forming close van der Waals contacts with L130
and R139 residues of Bcl-XL.
Several structural studies by experimental, computational
methodologies and peptide mimitics as well as inhibitors of
MDM2/p53 binding demonstrated that p53 contains three
important hydrophobic residues (F19, W23 and L26). Our residual
decomposition of MDM2/p53 results also depicted the same
(Table 4). The residual contribution analysis of Bcl-XL/SN15
simulation postulated that indeed these three residues of the SN15
peptide are major contributors for binding with protein (Table 7).
These three hydrophobic residues of SN15 occupy three
hydrophobic pockets (p2–p4) in a similar manner as BH3 peptides
(Figure 1). The residue L26 of SN15 superimposes well on
equivalent residue leucine which is well conserved in all the BH3
peptides. It occupies the p2 binding pocket and forms van der
Waals interactions in a similar way as BH3 peptides and
contributes in same level for binding with Bcl-XL (,25 kcal/
mol). The central hydrophobic residue tryptophan (W23) of SN15
resides at the p3 hydrophobic binding pocket and interacts
Figure 3. Stability of secondary structural features of Bcl-XL/SN15 complex. Secondary structural characteristics were calculated using DSSP
for total simulation to understand the stability and changes for the Bcl-XL/SN15 complex. The initial (7 residues) and final (9 residues) helix length of
the SN15 are represented with starting and ending residues of helix and highlighted by arrows. Initial and final frames of the protein represented as
cartoon model and labeled.
doi:10.1371/journal.pone.0026014.g003
MD Simulations of Bcl-XL/p53 Complex
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A142. A stable hydrogen bond is observed between epsilon
nitrogen atom of tryptophan and main chain carbonyl of E96.
This could be the possible reason for larger contribution of binding
energy of this residue for complex formation. The point mutation
(W23A) simulation results produced around 10 kcal/mol less
enthalpy (DH) compare to the wild type peptide simulation which
is in good agreement with experimental data (Table 2 and Table
S3). Our results postulated that tryptophan is the optimized option
for binding at p3 hydrophobic pocket than methionine (Bad) or
isoleucine (Bak). The Bcl-XL p4 hydrophobic pocket formed by
F97 and V141 residues provides space for another hydrophobic
residue (F19) of SN15. Though the phenyalanine is present in both
SN15 and Bad peptides the relative contribution of binding from
SN15 is less (,2 kcal/mol). In the case of SN15 the side chain of
F19 slightly dislocates from the p4 pocket due to the relative
binding orientation of the peptide. This could be the probable
reason for the lower contribution of SN15 at particular interaction.
In addition to these three crucial hot spot residues, several other
hydrophobic residues present on the SN15 peptide forms van der
Waals interactions with Bcl-XL binding pocket. Residue L22
which precedes important hydrophobic residue W23 shows
favorable contribution to binding by forming close contacts with
R139. Another hydrophobic residue L25 forms van der Waals
contacts with L130 and R139 residues of Bcl-XL. L25 is present in
an equivalent position as A8 of Bak peptide which exhibited
similar type of interactions with the protein. P27 of SN15 peptide
interacts considerably strong with the Bcl-XL binding pocket by
forming both hydrophobic and hydrogen bond interactions. The
proline ring resides on the top of the p1 pocket and form
hydrophobic interactions with side chains of L112, V126 and
F146. The main chain P27 carbonyl forms a stable hydrogen bond
interaction with Y101 side chain hydroxyl which is present on
BH3 binding region of Bcl-XL.
Besides hydrophobic interaction ability of SN15 with Bcl-XL,
several hydrophilic interactions were observed (Figure S3). The
residue S20 contributed 22.5 kcal/mol for binding, constituting
hydrogen bond with R100 of the protein. This hydrogen bond is
observed between side chains of the both residues. Another residue
Q16 forms several hydrogen bond interactions with E96, R100 of
a2 helix. Though the SN15 peptide forms several hydrophilic
residues, it lacks the charged residues at appropriate positions like
Bad/Bak. SN15 peptide has a negatively charged residue (D21)
that is conserved even in Bad and Bak peptides. Although, it is in a
conserved position, due to the binding orientation of SN15 peptide
the distance between the complimentary residue (R139) of Bcl-XL
and D21 of SN15 is high and is unable to reach and establish
either hydrogen bond or salt bridge. Salt bridge as well as
hydrogen bonding interactions was observed with aspartate
residue (D12) which is present at equivalent position of Bak
peptide. The calculated minimum distance between the side
chains of aspartate residue of SN15, Bak (D21, D12 respectively)
and arginine (R139) residue of Bcl-XL is around 0.7 nm which is
not optimal for any type of interaction. In the case of Bak, though
the side chains are far at initial stages of the simulation but around
2 ns time the distance of the side chains reduced to around 0.2 nm
and is sustained throughout the simulation (Figure S4). This
Table 2. Bind free energy (kcal/mol) and components for
different protein-peptide complexes.
System DHT DS DGbind DGbind (expt)
a
MDM2/p53 250.4 239.1 211.3 26.4 to 29.0
Bcl-XL/Bad 271.0 253.3 217.7 212.7
Bcl-XL/Bak 262.1 249.8 212.3 28.9 to 29.3
Bcl-XL/SN15 249.3 242.0 27.3 24.9
Bcl-XL/SN15W23A 234.8 237.0 2.2 NB
b
aExperimental values obtained from the previous studies [35,36,50,59–61].
bNB; no binding [50].
doi:10.1371/journal.pone.0026014.t002
Table 3. Components of binding free energy (in kcal/mol) of MDM2 with p53 peptide.
MDM2/p53 MDM2 p53 Delta
Average Std Average Std Average Std
ELE 22839.2 48.6 22282.1 43.5 2181.5 20.0 2375.6
VDW 2357.4 18.1 2274.5 16.0 211.0 5.7 271.9
GAS 21322.8 51.9 2934.8 49.0 59.5 21.4 2447.5
GBSUR 35.3 0.7 33.6 0.5 10.7 0.2 29.0
GB 21393.3 45.8 21329.9 39.5 2469.4 17.4 406.0
GBSOL 21358.0 45.4 21296.3 39.2 2458.7 17.3 397.0
GBELE 24232.5 18.4 23612.0 18.1 2651.0 6.4 30.5
GBTOT 22680.8 35.3 22231.1 33.7 2399.3 12.5 250.4
TSTRA 16.2 0 16.0 0 14.4 0 214.3
TSROT 16.0 0 15.9 0 13.3 0 213.1
TSVIB 1179.9 3.0 1023.8 3.5 167.9 1.4 211.8
TSTOT 1212.1 3.0 1055.7 3.5 195.5 1.4 239.1
DGbind 211.3
Electrostatic energy (ELE); van der Waals contribution (VDW); total gas phase energy (GAS); nonpolar contribution to the solvation free energy (GBSUR); the electrostatic
contribution to the solvation free energy (GB); sum of nonpolar and polar contributions to solvation (GBSOL); sum of the electrostatic solvation free energy and MM
electrostatic energy (GBELE); final estimated binding free energy (GBTOT); translational energy (TSTRA); rotational energy (TSROT); vibrational energy (TSVIB), total
entropic contribution (TSTOT); binding free energy (DGbind).
doi:10.1371/journal.pone.0026014.t003
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mentary residues which can interact strongly with the charged Bcl-
XL binding pocket. This could be the possible reason for negative
electrostatic values (DELE) obtained for the Bcl-XL/SN15 peptide
simulation.
Hot spot residues of Bcl-XL involved in binding with BH3/
SN15 peptides
Major contributors which contribute $21 kcal/mol for complex
formation were considered as hot spots of Bcl-XL for the heterodimer
formation (Figure S5A–5C). Although several residues are important
for all the complexes, few differences also were noticed. These
differences largely arise due to the length and helical nature as well as
binding orientation of the different peptides (Figure 4B–4D). The Bad
peptide covers maximum surface of the Bcl-XL binding pocket and is
composed of both hydrophobic as well as charged residues. Bak and
SN15 peptides occupy comparatively less space due to their length.
Nevertheless, all three peptides (Bad, Bak and SN15) interact with the
conserved hydrophobic pocket residues. The p1 hydrophobic pocket
residues F105, V126 and F146 are involved in interactions with h1
hydrophobic residues of the BH3 peptides and P27 of the SN15
peptide. All three residues are consistently engaged in favorable
binding energy with all the peptides. Though SN15 lacks hydrophobic
residue at equivalent position of h1 on BH3 peptides, P27 of SN15
shields the p1 site and forms hydrophobic interactions with these three
residues. In the case of F146, it contributes little less than the
benchmark contribution with SN15 peptide (20.8 kcal/mol). Anoth-
er notable difference is Y8 residue of Bad peptide establishes
interaction with L112 while Bak and SN15 interacts with L108
(Table 7). The p2 hydrophobic pocket residues, F97 and L130 are
consistently involved in favorable binding with all three peptide
hydrophobic conserved leucine residue. Other two hydrophobic
residues also contributed considerably with all the peptides.
Both Bad and Bak peptides consists of two negatively charged
successive amino acids (D17, E18 in Bad and D12 and D13 in
Bak). These residues extend their side chains and cover both sides
of the Bcl-XL binding pocket charged walls (Figure 5D and 5E).
They superimpose well in both the peptide binding conformations
and are suspected to form hydrogen bond as well as salt bridge
interactions with R139 and R100, respectively. But only in the
case of Bak peptide both aspartate residues interact with arginine
residues by either hydrogen bond interactions or salt bridges. This
observation was clearly reflected in the residual decomposition
analysis (Table 7). Both arginines R100 and R139 contributed
predominantly (23.5 and 25.1 kcal/mol, respectively), but the
Table 4. Residual decomposition analyses to recognize the important contributors of MDM2 and p53 peptide.
Residue (MDM2) Energy contribution (kcal/mol) Residue (p53) Energy contribution (kcal/mol)
M50 21.17 E17 20.15
K51 21.14 T18 21.59
L54 23.27 F19
a 26.58
L57 21.13 S20 0.32
G58 21D 2 1 20.1
I61 22.03 L22 22.26
M62 21.15 W23
a 24.9
Y67 21.17 K24 0.91
Q72 21.64 L25 21.06
H73 21.16 L26
a 23.99
V93 21.65 P27 21.95
R97 26.61 E28 0.27
I99 21.16 N29 20.84
Y100 21.81
aThree major contributing hydrophobic residues of p53 peptide (F19, W23 and L26) are highlighted as bold.
doi:10.1371/journal.pone.0026014.t004
Figure 4. Major contributing residues of MDM2 and Bcl-XL for
complex formation with SN15 and BH3 peptides. Pictorial
representation of important residues of MDM2 for complex formation
with p53 (A). The p53 peptide is shown in magenta cartoon and MDM2
protein is highlighted by surface representation. The major contributors
from both protein and peptide are represented by sticks and labeled.
The Bcl-XL protein and peptides Bad (B), Bak (C), SN15 (D) are
represented as cartoon model and major contributing residues are
shown as sticks. Important interacting regions of Bcl-XL such as BH1,
BH2 and BH3 are highlighted as magenta, red and gray, respectively.
doi:10.1371/journal.pone.0026014.g004
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reason could be due to unfavorable interactions with R139
because of close proximity to another positively charged residue
R13 on Bad peptide which causes charge repulsion. E18 is unable
to form any type of interactions with R100; instead it forms a
hydrogen bonding interaction with Y101. Residue Q16 of SN15
forms 2–3 hydrogen bond interactions with Bcl-XL. Main chain
carbonyl group interacts with R100 and its side chain form
hydrogen bonds with E96 side chain of the protein. Because of
these two interactions E96 and R100 contributed favorably for
complex formation (Figure S3).
Common features of p53 (SN15) responsible for dual
target binding
Residual decomposition and hot spot recognition for the
complex formation revealed that several hydrophobic residues of
the BH3 and SN15 peptides are forming similar type of
interactions with Bcl-XL (Figure 5). The three hydrophobic pillars
of p53 (F19, W23 and L26) which are crucial for MDM2/p53
binding recognition are indeed important in complex formation
with Bcl-XL. All these three residues occupy 3 out of 4 conserved
hydrophobic pockets (p2–p4) of the Bcl-2 family proteins.
Previously, attempts were made to develop potent Bcl-XL
inhibitors based a-helical peptidomimetics taking into consider-
ation of three hydrophobic residues such as L7, I10 and I14 (i, i+3,
and i+7) of Bak peptide [65,66]. These mimetics developed from
the BH3 peptide demonstrated binding towards Bcl-XL and also
with MDM2. Our recent finding revealed that even MDM2
potent inhibitor nutlin-3 and PMI (p53 mutant peptide) bind with
Bcl-2 family proteins [67]. These observations suggest that though
globular folding pattern of MDM2 and Bcl-2 proteins is different
they share similar binding with p53.
Another important similarity in binding pattern of p53 with Bcl-
XL and MDM2 (Figure 6) is the stable hydrogen bond interaction
between epsilon nitrogen atom of tryptophan (W23) side chain and
main chain carbonyl of E96 (Bcl-XL), L54 (MDM2). Our
simulations results in the present study postulated that P27 of
SN15 covers the first hydrophobic pocket (p1) and forms van der
Waals interactions with L112, V126 and F146. Recent crystal
structures of MDM2 and MDMX with PMI (p53 based mutant
peptide inhibitors) revealed that both the protein surfaces have an
extra 4th hydrophobic pocket. The proline residue which is
present at C-terminal end of PMI (TSFAEYWNLLSP) occupies
this extra binding pocket (Figure S6) of MDMX formed by V49,
M53, Y99 and L102. In MDM2 the equivalent residues are M50,
L54, Y100 and I103. Surprisingly this pocket is unable to
accommodate the proline residue of PMI due to the Y100
conformation. The point mutation studies clearly indicated that
the proline change affects negatively on binding with MDMX
protein. Despite these differences it’s clear that these two proteins
have 4th hydrophobic pocket similar as Bcl-2 proteins.
In conclusion, our present MD simulations coupled with
binding free energy calculations corroborated with our previous
NMR studies of binding pattern of SN15 with Bcl-XL. Residual
decomposition results demonstrated similarities in the binding
pattern between the BH3 and SN15 with Bcl-XL protein. Key
hydrophobic residues of p53 peptide (F19, W23 and L26), which
are crucial for MDM2 binding occupy the hydrophobic patch of
Bcl-XL in an identical manner as Bad and Bak peptides. Though
the SN15 satisfies the hydrophobic contribution similar to BH3
peptides, lack of charged interactions with the either sides of Bcl-
Table 6. Bcl-XL residues and their energy contribution for
each peptide.
Residue (Bcl-XL) Energy contribution (kcal/mol)
Bad Bak SN15
E96 - - 22.78
F97 23.35 22.5 22.53
R100 - 23.44 24.76
Y101 21.7 - -
A104 21.45 - -
F105 21.04 22.35 21.47
L108 - 21.24 22.26
Q111 - 22.56 -
L112 21.72 - -
Q125 21.03 - -
V126 23.46 21.75 21.25
E129 22.78 - -
L130 23.44 22.27 22.11
D133 24.65 - -
N136 - 22.3 -
G138 - 21.31 -
R139 - 25.11 -
V141 21.08 - -
A142 21.28 21.09 21.14
F146 21.4 21.35 -
L194 21.19 21.37 -
doi:10.1371/journal.pone.0026014.t006
Table 5. Components of binding free energy (in kcal/mol) of
Bcl-XL with SN15 peptide.
Bcl-XL/SN15 Bcl-XL SN15 Delta
Average Std Average Std Average Std
ELE 24796.6 77.2 24659.3 78.7 2326.4 31.7 189.1
VDW 2689.7 26.1 2600.2 25.2 212.0 5.8 277.5
GAS 21984.6 87.2 22048.1 87.6 248.1 32.5 111.6
PBSUR 58.4 1.48 57.1 1.38 11.7 0.2 210.5
PB 24081.4 75.0 23465.2 79.0 2465.7 30.2 2150.5
PBSOL 24023.0 74.3 23408.1 78.2 2454.0 30.1 2160.9
PBELE 28877.9 29.9 28124.5 28.6 2792.1 6.5 38.7
PBTOT 26007.6 46.4 25456.2 44.1 2502.0 12.5 249.3
TSTRA 16.7 0 16.6 0 14.5 0 214.4
TSROT 16.9 0 16.8 0 13.4 0 213.3
TSVIB 2110.7 8.5 1938.7 7.1 186.3 1.7 214.3
TSTOT 2144.4 8.5 1972.1 7.1 214.3 1.7 242.0
DGbind 27.3
Electrostatic energy (ELE); van der Waals contribution (VDW); total gas phase
energy (GAS); nonpolar contribution to the solvation free energy (PBSUR); the
electrostatic contribution to the solvation free energy (PB); sum of nonpolar and
polar contributions to solvation (PBSOL); sum of the electrostatic solvation free
energy and MM electrostatic energy (PBELE); final estimated binding free
energy (PBTOT); translational energy (TSTRA); rotational energy (TSROT);
vibrational energy (TSVIB), total entropic contribution (TSTOT); binding free
energy (DGbind).
doi:10.1371/journal.pone.0026014.t005
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PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e26014Figure 5. Hydrophobic and charged surface of Bcl-XL. The shallow hydrophobic pocket of Bcl-XL is shown with yellow color, positive and
negatively charged residues present on the walls of the pocket represented with blue and red, respectively. The hydrophobic residues of peptides
h1–h4 of Bad (A), Bak (B) and h2–h4 of SN15 (C) are highlighted as sticks which lock with hydrophobic pockets of Bcl-XL. Complimentary charged
residues on Bad (D), Bak (E), SN15 (F) are highlighted as sticks and labeled accordingly.
doi:10.1371/journal.pone.0026014.g005
Table 7. Residual contribution of BH3 (Bad, Bak) and SN15 peptides for complex formation with Bcl-XL.
Bad Energy contribution (kcal/mol Bak Energy contribution (kcal/mol SN15
a Energy contribution (kcal/mol
N1 1.65
L2 22.29
W3 20.14
A4 20.63
A5 22.81
Q6 22.28 G1 3.44
R7 20.68 Q2 20.96
Y8 22.88 V3 24.22
G9 21.67 G4 21.04 N29 2.66
R10 24.73 R5 23.4 E28 1.16
E11 0.97 Q6 22.82 P27 21.98
L12 23.3 L7 24.79 L26 24.95
R13 26.1 A8 22L 2 5 21.68
R14 20.69 I9 20.52 K24 20.46
M15 23.22 I10 24.27 W23 26.88
S16 1.98 G11 20.79 L22 22.1
D17 0.74 D12 20.56 D21 1.39
E18 1.2 D13 0.92 S20 22.56
F19 25.05 I14 21.7 F19 22.64
V20 21.54 N15 20.72 T18 20.19
D21 0.82 R16 20.6 E17 0.53
S22 1.35 Q16 25.72
F23 21.99 S15 2.17
K24 20.39
K25 0.17
aSN15 residues shown in reverse direction based on alignment with BH3 peptides (refer Figure 1E).
doi:10.1371/journal.pone.0026014.t007
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tryptophan residue of SN15 contributes dominantly for complex
formation and forms both hydrophobic and hydrogen bonding
interactions at third hydrophobic pocket of Bcl-XL. This residue
contributes better than equivalent residues of BH3 peptides (M15,
I10 of Bad and Bak peptides respectively). Analogous interaction
pattern was observed between W23 of p53 and MDM2. This
anchoring interaction of tryptophan in both complexes could be
one of the reasons for susceptibility for mutational changes which
causes decrease or total loss of binding [50,59]. Recent evidence of
nutlin-3 binding in Bcl-XL substantiated the importance of
tryptophan or tryptophan mimics for dual target binding [67].
Our results provide insights into the molecular basis for
recognition of p53 peptide in MDM2 and Bcl-XL and could be
helpful to develop inhibitors which can bind to both targets.
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ed using DSSP method in time dependent manner for
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understand the stability of the helical content of the
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residues are highlighted with sticks and hydrogen bonds
represented with dashed line.
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side chains of D21 (SN15), D12 (Bak) and R139 of Bcl-
XL.
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Figure S5 Residual decomposition and energy contri-
bution of each residue in complex simulations of Bcl-
XL/Bad (A), Bcl-XL/Bak (B), Bcl-XL/SN15 (C), and
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Figure S6 The p53 peptidomimetic (PMI) interaction
pattern with MDM2 (A), and MDMX (B). The trio
hydrophobic residues and terminal proline residues of PMI are
shown as sticks and labeled. The hypothetical fourth hydrophobic
pocket forming residues in MDM2 and MDMX are also
highlighted as sticks.
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Table S1 Components of binding free energy (in kcal/
mol) of Bcl-XL with Bad peptide.
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Figure 6. Hydrogen bonding pattern of p53 tryptophan residue. W23 residue of p53 or SN15 forms stable hydrogen bonding interaction
with main chain carbonyl of E96 of Bcl-XL are shown (A). Hydrogen bond interaction between W23 of p53 and main chain carbonyl of L54 residue of
MDM2 are shown (B). Hydrogen bond represented with black dotted line.
doi:10.1371/journal.pone.0026014.g006
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